Influvac® is an inactivated trivalent vaccine launched in 1962.
Influvac® contains the appropriate quantities of A and B virus strains recommended by the World Health Organization. These strains vary from year to year and therefore vaccines from previous years may not contain the current recommended virus strains.
The constituents of Influvac® for the 2018/2019 season, as recommended by the World Health Organization, are as follows:
Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains (propagated in fertilised hens’ eggs from healthy chicken flocks) per 0.5 ml dose:
This website is owned and managed by Mylan. This site has been developed for use by healthcare professionals, please click here to visit our public website. Influvac® Tetra is a registered trademark of Mylan N.V. and its affiliates.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare providers are asked to report any suspected adverse reactions. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. In order to support effective tracking and traceability of medicinal products, it is recommended that the brand name and batch number are recorded and used when reporting adverse events. Adverse events should be reported to Pharmacovigilance, Mylan, Building 4, Trident Place, Hatfield Business Park, Mosquito Way, Hatfield, Hertfordshire, AL10 9UL, on phone no. 0800 121 8267, Email: email@example.com